Effects of body weight on the efficacy and safety of oral anticoagulants for the prevention of VTE after hip and knee arthroplasty： a meta-analysis

YUAN Yao; LI Xinyu; SHAN Xuefeng; QIU Feng

doi:10.6039/j.issn.1001-0408.2022.23.15

您当前的位置：

首页 >

文章列表页 >

Effects of body weight on the efficacy and safety of oral anticoagulants for the prevention of VTE after hip and knee arthroplasty： a meta-analysis

更新时间：2023-02-22

- Effects of body weight on the efficacy and safety of oral anticoagulants for the prevention of VTE after hip and knee arthroplasty： a meta-analysis
- ZHONGGUO YAOFANG Vol. 33, Issue 23, Pages: 2895-2900(2022)
- 作者机构：
  
  重庆医科大学附属第一医院药学部，重庆　400010
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2022.23.15
  CLC： R969.3;R973⁺.2
- Published：15 December 2022，
  
  Received：28 July 2022，
  
  Revised：09 October 2022，
扫描看全文
袁尧,李欣宇,单雪峰等.体质量影响髋膝关节置换术后口服抗凝药物预防VTE有效性和安全性的Meta分析 ^Δ[J].中国药房,2022,33(23):2895-2900.

YUAN Yao,LI Xinyu,SHAN Xuefeng,et al.Effects of body weight on the efficacy and safety of oral anticoagulants for the prevention of VTE after hip and knee arthroplasty： a meta-analysis[J].ZHONGGUO YAOFANG,2022,33(23):2895-2900.
袁尧,李欣宇,单雪峰等.体质量影响髋膝关节置换术后口服抗凝药物预防VTE有效性和安全性的Meta分析 ^Δ[J].中国药房,2022,33(23):2895-2900. DOI： 10.6039/j.issn.1001-0408.2022.23.15.

YUAN Yao,LI Xinyu,SHAN Xuefeng,et al.Effects of body weight on the efficacy and safety of oral anticoagulants for the prevention of VTE after hip and knee arthroplasty： a meta-analysis[J].ZHONGGUO YAOFANG,2022,33(23):2895-2900. DOI： 10.6039/j.issn.1001-0408.2022.23.15.

摘要

目的

系统性评价体质量对新型口服抗凝药（NOACs）、阿司匹林用于全髋关节置换术、全膝关节置换术（以下统称“髋膝关节置换术”）后预防静脉血栓栓塞（VTE）的有效性和安全性的影响，为合理用药提供循证参考。

方法

计算机检索PubMed、Embase、Cochrane library，收集含有以体质量或体质量指数[BMI 18.5～＜25 kg/m

为正常体质量，BMI 25～30 kg/m

为超重，BMI＞30 kg/m

为肥胖（其中BMI＞40 kg/m

为病态肥胖）]为亚组比较NOACs、阿司匹林和低分子肝素有效性和（或）安全性的随机对照试验（RCT）和非RCT研究。检索时间为建库起至2022年6月30日。筛选文献、提取数据后，采用Cochrane系统评价员手册推荐的偏倚风险评估工具RoB 2.0评价RCT研究的质量，采用纽卡斯尔-渥太华量表评估非RCT研究的质量。采用RevMan 5.4软件进行Meta分析。

结果

共纳入6篇文献，包含3项系列RCT汇总研究、3项非RCT研究。Meta分析结果显示，在不同BMI亚组中，正常体质量患者[OR＝0.63，95%CI（0.26，1.51），

＝0.30]、超重患者[OR＝0.48，95%CI（0.22，1.04），

＝0.06]、肥胖患者[OR＝0.70，95%CI（0.40，1.25），

＝0.23]使用NOACs在降低主要VTE及VTE相关死亡率方面与依诺肝素比较，差异均无统计学意义。主要出血事件率、主要+临床相关非主要出血事件率方面，NOACs在不同BMI亚组中的安全性与依诺肝素相当（

＞0.05）。使用NOACs及阿司匹林的肥胖/病态肥胖患者对比正常/超重患者的总VTE率[OR＝1.28，95%CI（0.68，2.40），

＝0.45]、症状性VTE及全因死亡率[OR＝1.26，95%CI（0.81，1.95），

＝0.30]和主要出血事件率[OR＝0.79，95%CI（0.58，1.08），

＝0.14]比较，差异均无统计学意义。

结论

体质量对NOACs及阿司匹林预防髋膝关节置换术后VTE有效性和安全性的影响并不显著，支持超重、肥胖患者接受NOACs或阿司匹林预防VTE。

Abstract

OBJECTIVE

To systematically review the effects of body weight on the efficacy and safety of novel oral anticoagulants （NOACs） or aspirin for the prevention of venous thromboembolism （VTE） after total hip arthroplasty and total knee arthroplasty （hereinafter referred to as “hip and knee arthroplasty”）.

METHODS

Retrieved from PubMed， Embase and Cochrane library， randomized controlled trial （RCT） and non-RCT about the effectiveness and/or safety of NOACs， aspirin and low-molecular heparin by subgrouping according to body weight or body weight index [BMI 18.5-＜25 kg/m

as normal body mass， BMI 25-30 kg/m

as overweight， and BMI＞30 kg/m

as obesity （of them， BMI＞40 kg/m

as morbid obesity）] were collected from the inception to June 30， 2022. After literature screening and data extraction， the quality of RCT was evaluated with bias risk assessment tool RoB 2.0 recommended by Cochrane system evaluator manual. The Newcastle-Ottawa scale was used to evaluate the quality of non-RCT. Meta-analysis was performed by using RevMan 5.4 software.

RESULTS

A total of 6 literatures， containing 3 series of RCT pooled studies and 3 non-RCTs were included. The results of meta-analysis showed that among different BMI subgroups， there was no statistical significance in reducing major VTE and VTE-related mortality of patients with normal body mass patients [OR＝0.63， 95%CI（0.26，1.51），

＝0.30]， overweight patients [OR＝0.48，95%CI（0.22，1.04），

＝0.06] and obese patients [OR＝0.70，95%CI（0.40，1.25），

＝0.23] by NOACs， compared with enoxaparin. The safety of NOACs was comparable to that of enoxaparin in different BMI subgroups in terms of the incidence of major bleeding events and major+clinically relevant non-major bleeding events （

＞0.05）. There was no statistical significance in the incidences of total VTE [OR＝1.28， 95%CI （0.68，2.40），

＝0.45]， symptomatic VTE and all-cause mortality [OR＝1.26， 95%CI （0.81，1.95），

＝0.30] and major bleeding [OR＝0.79， 95%CI （0.58，1.08），

＝0.14] in obese/morbidly obese patients using NOACs and aspirin， compared with normal/overweight patients.

CONCLUSIONS

The impact of body weight on the efficacy and safety of NOACs and aspirin for the prevention of VTE after hip and knee arthroplasty is not significant， and this study supports that overweight and obese patients receive NOACs or aspirin for VTE prevention.

关键词

体质量关节置换术静脉血栓栓塞新型口服抗凝药阿司匹林Meta分析

Keywords

arthroplastyvenous thromboembolismnovel oral anticoagulantsaspirinmeta-analysis

references

MATHARU G S，KUNUTSOR S K，JUDGE A，et al. Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement：a systematic review and meta-analysis of randomized clinical trials[J]. JAMA Intern Med，2020，180（3）：376-384.

邱贵兴. 中国骨科大手术静脉血栓栓塞症预防指南[J/OL]. 中华关节外科杂志（电子版），2009，3（3）：380-383[2022-09-10]. https：//kns.cnki.net/kns8/defaultresult/indexhttps://kns.cnki.net/kns8/defaultresult/index.

MARTIN K，BEYER-WESTENDORF J，DAVIDSON B L，et al. Use of the direct oral anticoagulants in obese patients：guidance from the SSC of the ISTH[J]. J Thromb Haemost，2016，14（6）：1308-1313.

AFSHIN A，REITSMA M B，MURRAY C J L. Health effects of overweight and obesity in 195 countries[J]. N Engl J Med，2017，377（15）：1496-1497.

NCD Risk Factor Collaboration （NCD-RisC）. Trends in adult body-mass index in 200 countries from 1975 to 2014：a pooled analysis of 1 698 population-based measurement studies with 19·2 million participants[J]. Lancet，2016，387（10026）：1377-1396.

MALIK A H，YANDRAPALLI S，SHETTY S，et al. Impact of weight on the efficacy and safety of direct-acting oral anticoagulants in patients with non-valvular atrial fibrillation：a meta-analysis[J]. Europace，2020，22（3）：361-367.

LI X Y，ZUO C C，JI Q Y，et al. Body mass index influence on the clinical outcomes for nonvalvular atrial fibrillation patients admitted to a hospital treated with direct oral anticoagulants：a retrospective cohort study[J]. Drug Des Devel Ther，2021，15：1931-1943.

MALTENFORT M. CORR insights®：is obesity associated with increased risk of deep vein thrombosis or pulmonary embolism after hip and knee arthroplasty? A large database study[J]. Clin Orthop Relat Res，2019，477（3）：533-535.

BUCK M M，HADDON A M，PANECCASIO A，et al. Safety and efficacy of rivaroxaban and apixaban in patients with increased body mass：a systematic review [J]. Clin Drug Investigat，2021，41（4）：353-369.

RICHARDSON S S，SCHAIRER W W，SCULCO P K， et al. Comparison of pharmacologic prophylaxis in prevention of venous thromboembolism following total knee arthroplasty[J]. Knee，2019，26（2）：451-458.

PAGE M J，MCKENZIE J E，BOSSUYT P M，et al. The PRISMA 2020 statement：an updated guideline for repor- ting systematic reviews[J]. J Clin Epidemiol，2021，134：178-189.

STERNE J A C，SAVOVIĆ J，PAGE M J，et al. RoB 2：a revised tool for assessing risk of bias in randomised trials[J]. BMJ，2019，366：l4898.

STANG A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol，2010，25（9）：603-605.

ERIKSSON B I，DAHL O E，FEURING M，et al. Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery：a pooled analysis[J]. Thromb Res，2012，130（5）：818-820.

KRAUSS E S，CRONIN M，DENGLER N，et al. The effect of BMI and gender on bleeding events when rivaroxaban is administered for thromboprophylaxis following total hip and total knee arthroplasty[J]. Semin Thromb Hemost，2019，45（2）：180-186.

PINEO G F，GALLUS A S，RASKOB G E，et al. Apixaban after hip or knee arthroplasty versus enoxaparin：efficacy and safety in key clinical subgroups[J]. J Thromb Haemost，2013，11（3）：444-451.

ROSENCHER N，SAMAMA C M，FEURING M，et al. Dabigatran etexilate for thromboprophylaxis in over 5 000 hip or knee replacement patients in a real-world clinical setting[J]. Thromb J，2016，14：8.

TANG A，SICAT C S，SINGH V，et al. Aspirin use for venous thromboembolism prevention is safe and effective in overweight and obese patients undergoing revision total hip and knee arthroplasty[J]. J Arthroplasty，2021，36（7S）：S337-S344.

TURPIE A G G，LASSEN M R，ERIKSSON B I，et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies[J]. Thromb Haemost，2011，105（3）：444-453.

ERIKSSON B I，DAHL O E，ROSENCHER N，et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement：a randomised，double-blind，non-inferiority trial[J]. Lancet，2007，370（9591）：949-956.

ERIKSSON B I，DAHL O E，ROSENCHER N，et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement：the RE-MODEL randomized trial[J]. J Thromb Haemost，2007，5（11）：2178-2185.

ERIKSSON B I，BORRIS L C，FRIEDMAN R J，et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J]. N Engl J Med，2008，358（26）：2765-2775.

KAKKAR A K，BRENNER B，DAHL O E，et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty：a double-blind，randomised controlled trial[J]. Lancet，2008，372（9632）：31-39.

LASSEN M R，AGENO W，BORRIS L C，et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J]. N Engl J Med，2008，358（26）：2776-2786.

TURPIE A G，LASSEN M R，DAVIDSON B L，et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty （RECORD4）：a randomised trial[J]. Lancet，2009，373（9676）：1673-1680.

LASSEN M R，GALLUS A，RASKOB G E，et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement[J]. N Engl J Med，2010，363（26）：2487-2498.

LASSEN M R，RASKOB G E，GALLUS A，et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement （ADVANCE-2）：a randomised double-blind trial[J]. Lancet，2010，375（9717）：807-815.

ERIKSSON B I，DAHL O E，HUO M H，et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty （RE-NOVATE Ⅱ*）. A randomised，double-blind，non-inferiority trial[J]. Thromb Haemost，2011，105（4）：721-729.

ROSENCHER N，FROSTICK S，FEURING M，et al. Real-world study of dabigatran etexilate for thromboprophylaxis in over 5 000 hip or knee replacement patients：favourable safety profile in subgroups with different BMI，renal function and age[J]. Blood，2012，120（21）：1160.

YI Y H，GONG S，GONG T L，et al. New oral anticoagulants for venous thromboembolism prophylaxis in total hip and knee arthroplasty：a systematic review and network meta-analysis[J]. Front Pharmacol，2021，12：775126.

凌涛，徐瑞娟，王斌，等. 新型口服抗凝剂用于关节置换术后有效性和安全性的系统评价[J]. 中国循证医学杂志，2020，20（9）：1038-1044.

COHEN A T，PAN S，BYON W，et al. Efficacy，safety，and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism：insights from AMPLIFY[J]. Adv Ther，2021，38（6）：3003-3018.

NOVAK A R，SHAKOWSKI C，TRUJILLO T C，et al. Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism[J]. J Thromb Thrombolysis，2022，54（2）：276-286.

MARTIN K A，BEYER-WESTENDORF J，DAVIDSON B L，et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism：updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation[J]. J Thromb Haemost，2021，19（8）：1874-1882.

ALOI K G，FIERRO J J，STEIN B J，et al. Investigation of direct-acting oral anticoagulants and the incidence of venous thromboembolism in patients weighing ≥120 kg compared to patients weighing ＜120 kg[J]. J Pharm Pract，2021，34（1）：64-69.

HALBUR C R，GULBRANDSEN T R，WEST C R，et al. Weight-based aspirin dosing may further reduce the incidence of venous thromboembolism following primary total joint arthroplasty[J]. J Arthroplasty，2021，36（12）：3986-3992.

ROCCA B，FOX K A A，AJJAN R A，et al. Antithrombotic therapy and body mass：an expert position paper of the ESC Working Group on Thrombosis[J]. Eur Heart J，2018，39（19）：1672-1686f.

HUMPHREY T J，O'BRIEN T D，MELNIC C M，et al. Morbidly obese patients undergoing primary total joint arthroplasty may experience higher rates of venous thromboem- bolism when prescribed direct oral anticoagulants vs aspirin[J]. J Arthroplasty，2022，37（6）：1189-1197.

LEWIS S，GLEN J，DAWOUD D，et al. Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement：a systematic review and network meta-analysis[J]. Lancet Haematol，2019，6（10）：e530-e539.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of ivabradine on vascular endothelial function in patients with coronary artery disease： a meta-analysis

Meta-analysis about ADRB1 Arg389Gly polymorphism on the efficacy of bisoprolol

Meta-analysis of efficacy and safety of aspirin versus other anticoagulants in the prevention of thromboembolism after orthopedic surgery

Meta-analysis of the efficacy and safety of Saccharomyces boulardii versus Bifidobacterium triple live bacteria in the treatment of pediatric diarrhea

Systematic review and meta-analysis of health state utility for global patients with hemophilia

Related Author

CHEN Congling

YANG Xian

WU Han

YING Jiachen

ZHANG Ruobin

LAN Xi

ZHANG Jinping

ZHANG Tianqi

Related Institution

Dept. of Cardiology， Nanjing Drum Tower Hospital

School of Basic Medicine and Clinical Pharmacy， China Pharmaceutical University

Dept. of Pharmacy， Nanjing Drum Tower Hospital

Dept. of Pharmacy， Beijing Hospital/National Center of Gerontology/Institute of Geriatric Medicine， Chinese Academy of Medical Science/Beijing Key Laboratory of Assessment for Clinical Risk and Individual Application of Drugs

Dept. of Cardiology， General Hospital of Eastern Theater Command

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰